News Release

Long-Term Safety and Efficacy Submission filed

Date: Feb 27, 2002

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") is pleased to announce that it has received the screening Acceptance Notification from Health Canada that its submission for a long-term efficacy and safety study of Tetrodin(tm)/Tectin(tm) in pain and opiate withdrawal treatment has been accepted for review.

The Company requested this study in order to offer patients the ability to obtain our drug in the event they received benefit from its use during Phase II studies. This multi-center, open label, multi-dose, long-term safety and efficacy continuation study of Tetrodin(tm)/Tectin(tm) in patients with pain or opioid withdrawal, in the Company's view, is the only humane method of handling the difficult task of ensuring supply against benefit. This would preclude preventing or delaying patients benefiting from continued treatment before product commercialization. Although our decision is not a pre-requisite to carrying out our pain and opiate withdrawal studies, the efficacy and safety outcome on the prolonged use of Tetrodin(tm)/Tectin(tm) would be beneficial.

According to current regulations, there is a 30 day default period for Health Canada to review the application. Pursuant to our proposed study protocol being accepted, the Company will be granted permission to initiate this study during the last half of March.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substance using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Howard Milne, V.P. Corporate Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.